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Summary 
 
Background 
Photodynamic therapy requires the combined interaction of a photosensitiser, light 
and oxygen to ablate target tissue. In this study we examined the effect of iron 
chelation and oxygen environment manipulation on the accumulation of the clinically 
useful photosensitiser protoporphyrin IX (PpIX) within human squamous epithelial 
carcinoma cells and the subsequent ablation of these cells on irradiation. 
 
Methods 
Cells were incubated at concentrations of 5%, 20% or 40% oxygen for 24 h prior to 
and for 3 h following the administration of the PpIX precursors aminolevulinic acid 
(ALA), methyl aminolevulinate (MAL) or hexylaminolevulinate (HAL) with or without 
the iron chelator 1,2-diethyl-3-hydroxypyridin-4-one hydrochloride (CP94). PpIX 
accumulation was monitored using a fluorescence plate reader, cells were irradiated 
with 37 J/cm2 red light and cell viability measured using the neutral red uptake assay. 
 
Results 
Manipulation of the oxygen environment and/or co-administration of CP94 with PpIX 
precursors resulted in significant changes in both PpIX accumulation and 
photobleaching. Incubation with 5% or 40% oxygen produced the greatest levels of 
PpIX and photobleaching in cells incubated with ALA/MAL. Incorporation of CP94 
also resulted in significant decreases in cell viability following administration of 
ALA/MAL/HAL, with oxygen concentration predominantly having a significant effect 
in cells incubated with HAL. 
Conclusions 
Experimentation with human squamous epithelial carcinoma cells has indicated that 
the iron chelator CP94 significantly increased PpIX accumulation induced by each 
PpIX congener investigated (ALA/MAL/HAL) at all oxygen concentrations employed 
(5%/20%/40%) resulting in increased levels of photobleaching and reduced cell 
viability on irradiation. Further detailed investigation of the complex relationship of 
PDT cytotoxicity at various oxygen concentrations is required. It is therefore 
concluded that iron chelation with CP94 is a simple protocol modification with which 
it may be much easier to enhance clinical PDT efficacy than the complex and less 
well understood process of oxygen manipulation. 
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Introduction 
 
Photodynamic therapy (PDT) requires the combined interaction of a photosensitiser, 
light and molecular oxygen to ablate target tissue. Despite PDT being an established 
treatment modality within the field of dermatology [1] it has yet to become a widely 
used therapy. This may partly be due to limitations of current PDT regimens, for 
example, in achieving selective and sufficient accumulation of photosensitiser in the 
target tissue, optimising the light dosimetry, successfully delivering the light to the 
target areas and finally resolving the issue of the limited availability of molecular 
oxygen in the target tissue [2].  
 
Oxygen is consumed in the photochemical reactions required for successful 
photodynamic therapy [3]. The photosensitiser in its excited triplet state can react 
with ground state molecular oxygen to undergo the type II photochemical reaction in 
which oxidised products and/or singlet oxygen are formed [4]. The oxidised products 
can then undergo type I photochemical reactions producing other cytotoxic species 
which along with singlet oxygen ablate tissue. Tissue destruction can arise from 
direct cytotoxicity, vascular damage, and through stimulation of host immune 
responses [4]. However, oxygen can be consumed within these photochemical 
reactions more rapidly than it can be replenished [5] and therefore can be a rate-
limiting parameter. In addition, PDT can induce vascular shutdown, decreasing blood 
flow in both normal and tumour vessels, which results in hypoxia [6]. Hypoxia can 
reduce the PDT effect as well as stabilising the hypoxia-inducible factor-1 protein 
(HIF-1) which increases vascular endothelial growth factor (VEGF) expression. The 
increased production and secretion of VEGF is thought to contribute to tumour 
survival and regrowth via angiogenesis, glycolysis, erythropoiesis and apoptotic 
inhibition [7]. Finally, the cellular microenvironment of tumours tends to be hypoxic 
relative to normal tissue, which may influence protoporphyrin IX (PpIX) production 
and thus compromise PDT efficacy. This factor has therefore, made the investigation 
of the effects of oxygen concentration on both PpIX production and subsequent cell 
viability following irradiation a priority in both previous [8] and future research.  
 
Manipulating levels of molecular oxygen and/or being able to effectively replenish 
diminished levels of oxygen could be clinically useful for PDT and so research is 
taking place to try to optimise current PDT treatment regimes. Previous methods to 
potentially enhance the mechanism of action of PDT through oxygen manipulation 
have included the use of light dose fractionation [8], inhalation of carbogen or 100% 
normobaric oxygen (NBO) [9] or being subjected to hyperbaric oxygen (HBO) [9,10]. 
Other strategies to increase PDT sensitivity by modulating skin oxygen tension 
include hyperthermia, and perfluorocarbons [11].  
 
This in vitro study investigated how differences in the oxygen environment, prior to 
and following the administration of the PpIX precursors aminolevulinic acid (ALA), 
methyl aminolevulinate (MAL) or hexyl aminolevulinate (HAL) with or without the iron 
chelator 1,2-diethyl-3-hydroxypyridin-4-one  hydrochloride (CP94), affected the PpIX 
fluorescence produced within human squamous epithelial carcinoma cells. 
Additionally, the effect PpIX-induced PDT with iron chelation at different oxygen 
concentrations had on cell viability was also investigated.  
Materials and Methods 
Chemicals and cells 
Unless otherwise stated all reagents and chemicals were supplied by Sigma-Aldrich 
Chemical Company (Poole, UK). The A431 (human squamous epithelial carcinoma) 
cells were purchased from the European Collection of Cell Cultures (ECACC, 
Wiltshire, UK). Under aseptic conditions in a class II laminar flow cabinet, cells were 
cultured in Eagle’s minimum essential medium (EMEM) with 10% foetal calf serum 
(FCS, standardised to give an iron concentration between 450 and 600 g/100 g), 
2% (200 mM) L-glutamine (2 mM final concentration) and 2% penicillin (200 U mL−1 
final concentration) and streptomycin solution (200 g mL−1 final concentration). 
10 mM stock solutions of ALA/MAL/HAL were prepared in phosphate buffered saline 
(PBS), adjusted to physiological pH (pH 7.4) using NaOH (0.5 mM), filter sterilised 
(0.22 m  Millipore) and stored at −20 ◦C for up to one month. Cells were grown in 
5% CO2, 20% O2, at 37 ◦C and left to grow until 70% confluent at which time cells 
were routinely passaged (every 3-5 days). 
 
Oxygen manipulation 
A431 cells were seeded into 2 x 96-well plates (Corning, NY, USA) at a density of 1 
x 105 cells per mL (104 cells per well) and left to adhere in 5% CO2, 20% O2, at 37 ◦C 
for 24 h. Following this, cells were incubated for a further 24 h in 5% CO2, at 37 ◦C 
and in 5, 20 or 40% O2. The desired oxygen environment was achieved using a Tri-
gas incubator (MCO-18M, Sanyo, San Diego, USA). After the elapsed 24 h 
incubation all medium was aspirated from the wells of both plates and 100 l of 
appropriate test solution; modified EMEM + ALA/MAL/HAL ± CP94 (ALA, 250 M; 
MAL, 1000 M; HAL, 10 M; CP94, 150 M) was added to each well (5 wells 
per test solution), under dark room conditions. These doses were chosen based on 
results from previous work within the group which showed at the doses employed 
maximum PpIX fluorescence with minimal dark toxicity could be achieved [12]. Both 
plates were incubated for a further 3 h to allow PpIX accumulation to occur. 
 
PpIX fluorescence monitoring in vitro 
Following the elapsed 3 h, the plates were removed from the incubator and the lids 
taped to minimise any change to the oxygen environment. Both plates were then 
read for ‘pre’ PpIX fluorescence levels (prior to light irradiation) using a fluorescence 
plate reader (Synergy HT; BIO-TEK, Germany). Measurements were taken from the 
bottom of the plate wells with a 400 ± 30 nm excitation filter and a 645 ± 40 nm 
emission filter in place. Following the ‘pre’ fluorescence measurements of the two 
plates, one plate was subjected to red light irradiation (Aktilite, Galderma, UK, 
37 J/cm2, 635 ± 2 nm) whilst the other remained in the dark as the dark control. 
Finally, both plates were measured for ‘post’ PpIX fluorescence levels (following light 
irradiation). 
 
Neutral red uptake (NRU) assay  
Following ‘post’ PpIX fluorescence measurements the medium containing the test 
solutions was removed from the wells and cells were washed three times with PBS. 
A volume of 100 l serum free medium per well containing neutral red (40 g ml−1) was 
then added, and the plate returned to the incubator for a further 2 h. Following this 
the neutral red medium was removed, the cells washed with 150 l of PBS and neutral 
red destain solution (50% (v/v) 96% ethanol; 49% (v/v) deionised water; 1% (v/v) 
glacial acetic acid) was added to the wells. Finally, plates were rapidly shaken for a 
minimum of 10 minutes and the level of neutral red uptake, which is directly proportional 
to the amount of live cells in the cell culture, was measured using the excitation and 
emission wavelengths 530 nm (30 nm bandwidth) and 645 nm (40 nm bandwidth), 
respectively [13]. 
 
Data analysis and statistics 
For the 96-well test plates the first 5 wells contained control cells incubated with 
modified EMEM only (blank controls). The PpIX fluorescence measurements from 
these wells were used to remove natural cellular PpIX autofluorescence from 
all subsequent measurements made from the same plate. For the cell viability data 
collected, the viability in each test group was recorded and cell viability was 
displayed as a percentage of the untreated control group within each individual 
oxygen concentration. All data points in the figures represent mean values from 
experiments carried out in triplicate. Statistical significance between individual 
groups was determined using the Student’s t-test and an ANOVA was employed 
when considering differences between data sets.
Results 
Pre and post PpIX fluorescence 
Following exposure to an oxygen concentration of 5%, 20% or 40% and incubation 
with ALA/MAL/HAL ± CP94, prior to light irradiation and following light irradiation 
‘pre’ and ‘post’ PpIX fluorescence levels were recorded, respectively. As expected, 
the observed trend was a decrease in PpIX fluorescence following light irradiation 
(Fig. 1A-F) indicating that PpIX photobleaching had occurred during the light delivery. 
With all three pro-drugs significantly (p < 0.05) more PpIX fluorescence was 
observed pre-irradiation when CP94 was co-administered (Fig. 1A-F) at all three 
oxygen concentrations investigated. At each oxygen concentration the greatest 
levels of PpIX fluorescence prior to light irradiation were observed for the cells 
incubated with 1000 M MAL ± CP94 (in the range of 25-111 arbitrary units (a.u.); 
Fig. 1C-D), followed by cells incubated with 250 M ALA ± CP94 (in the range of 10-
79 a.u.; Fig. 1A-B). The least amount of PpIX fluorescence prior to light irradiation 
was observed for the cells incubated with 10 M HAL ± CP94 (in the range of 5-61 
a.u.; Fig. 1E-F). Comparison of the results produced by each pro-drugs administered 
indicated that greater levels of PpIX fluorescence were achieved when cells were 
incubated with 1000 M MAL ± CP94 compared to levels achieved when cells were 
incubated with 10 M HAL ± CP94 (ANOVA, p < 0.05). When levels of PpIX 
fluorescence between 1000 M MAL ± CP94 and 250 M ALA ± CP94, and between 
250 M ALA ± CP94 and 10 M HAL ± CP94 were compared using ANOVA to 
detect any significant difference (p < 0.05) none was found (p = 0.153 and p = 0.463, 
respectively).  
 
Following incubation with 250 M ALA/10 M HAL and subjection to 5%/20%/40% 
oxygen the observed trend for the level of ‘pre’ PpIX fluorescence  achieved was in 
the order 5% > 20% > 40% (Fig. 1A and E). When either pro-drug was combined 
with CP94 and subjected to 5%/20%/40% oxygen (Fig. 1B and F), levels of ‘pre’ 
PpIX produced were increased significantly at all three oxygen concentrations 
tested (p < 0.05). Following incubation with MAL and subjection to 5%/20%/40% 
oxygen the observed trend for the level of ‘pre’ PpIX achieved was in the order 5% > 
40% > 20% (Fig. 1C). When coincubated with CP94 levels of PpIX produced were 
again observed to increase at all three oxygen concentrations (p < 0.05), with the 
greatest amount of PpIX produced when cells were incubated with 1000 M 
MAL + CP94 at 40% oxygen (Fig. 1D). 
 
Measurement of PpIX photobleaching 
PpIX photobleaching occurs when the reactive oxygen species (ROS) produced 
during the PDT photochemical reactions permanently alter PpIX. A positive 
correlation between PpIX photobleaching and cellular damage has been previously 
reported [14-17] and it is therefore a good indicator of PDT effectiveness. The 
difference between the ‘pre’ and ‘post’ PpIX fluorescence readings can be attributed 
to PpIX photobleaching and so these measurements were quantified and compared 
as both the percentage of preirradiation PpIX levels bleached on irradiation as well 
as the absolute level of PpIX photobleaching in arbitrary units (Fig. 2). Although no 
significant difference was observed when the percentage of PpIX photobleached 
was compared between corresponding treatment groups (Fig. 2A), there appeared to 
be a trend of increased PpIX photobleaching when each pro-drug was coincubated 
with CP94 (Fig. 2B). Using a Student’s t-test to compare each of the pro-drug 
alone and pro-drug + CP94 data sets, revealed a significant increase in PpIX 
photobleaching for all three pro-drugs when coincubated with CP94 at any of the 
oxygen concentrations tested (p < 0.05); with the only exception being 1000 M 
MAL + CP94 compared to 1000 M MAL alone at 5% oxygen which did not reach 
significance at this level. When the levels of PpIX photobleaching between the three 
oxygen concentration data sets were compared using an ANOVA to detect any 
significant difference (p > 0.05) none was found. 
 
 
Cell viability 
Following irradiation, the viability of cells was assessed with the NRU assay. No 
significant difference in cell viability was observed between the different oxygen 
concentrations (p > 0.05) for cells incubated with 250 M ALA or 1000 M 
MAL alone (Fig. 3A and B). However when the cells were coincubated with 250 M 
ALA + CP94 a significant decrease was observed at 20% oxygen compared to 40% 
(Fig. 3A). When the cells were coincubated with 1000 M MAL + CP94 a  
significant decrease at 5% oxygen compared to 40% (Fig. 3B) was detected. For 
cells incubated with 10 M HAL ± CP94 the observed trend was a decrease in cell 
viability in the order of 5% > 40% > 20% oxygen concentration (Fig. 3C). With 
and without iron chelation a significant difference in cell viability was detected 
between the 5 and 20% and between the 40 and 20% oxygen concentrations (p < 
0.05) with significantly more cytotoxicity occurring with 20% oxygen than with 40% 
oxygen. Notably, following incubation of 10 M HAL ± CP94 at 5% oxygen no 
significant change in cell viability was observed (Fig. 3C).  
 
When comparing the percentage of cell viability observed at the same oxygen 
concentrations between prodrug alone and prodrug + CP94 significant differences 
were detected between 250 M ALA alone and 250 M ALA + CP94 at 20 and 
40% oxygen (p < 0.05; Fig. 3A). In addition, a significant difference was detected 
between 10 M HAL alone and 10 M HAL + CP94 at 20% and 40% oxygen (p < 
0.05; Fig. 3C). No significant difference in cell viability was observed between 1000 
M MAL alone and 1000 M MAL + CP94 at any of the oxygen concentrations 
tested (p > 0.05; Fig. 3B). 
 
Discussion 
During PpIX-induced PDT the combined interaction of PpIX, light of a specific 
wavelength and oxygen are utilised to ablate tumour cells. Administration of the 
porphyrin precursors ALA/MAL/HAL increased the synthesis of the endogenously 
produced photosensitiser PpIX within tumour cells (Fig. 1), and following the 
excitation of PpIX by light, in the presence of molecular oxygen induced cell death 
(Fig. 3). Oxygen is known to be essential for successful PDT to occur [18] and due to 
its consumption within these photochemical reactions oxygen is a rate-limiting factor 
of the therapy. By employing iron chelators PpIX accumulation can be enhanced 
further (Fig. 1) and by manipulating the oxygen environment the effectiveness of 
PDT may be optimised. Therefore in this study, A431 human squamous epithelial 
carcinoma cells were incubated with PpIX precursors with and without iron chelation 
whilst being subjected to an oxygen environment of 5%, 20% or 40%. PpIX 
fluorescence measurements were taken prior to and following red light irradiation 
and subsequent cell death was also measured. It was noted that significantly greater 
PpIX fluorescence occurred preirradiation when the iron chelator, CP94 was 
administered (Fig. 1). Also that substantial photobleaching occurred in all the groups 
on irradiation (Fig. 2) and this was significantly greater in the iron chelator groups 
(except with MAL at 5% oxygen). Taken together this suggested that the addition of 
an iron chelator resulted in a significant increase in the level of PpIX synthesis. 
However, as fluorescence was only measured at an entire well level we are unable 
to ascertain how much of this PpIX remained within cells following synthesis. 
 
It is widely accepted that tumour cells tend to be more hypoxic compared to normal 
cells and it has been suggested that hypoxic cells are less affected by porphyrins 
and light [19], and as a result may not be affected as much by reducing fluence rate 
or light fractionation [20]. Interestingly Wyld et al. [21] observed an increase in PpIX 
production under hyperoxic conditions when cells were incubated at 21% oxygen 
and compared with hypoxic conditions (<5% oxygen), although they did not consider 
oxygen concentrations higher than this. More direct effects of hyperoxygenation 
have also been investigated. One study [9] demonstrated that hyperoxygenation 
could improve tumour response by enhancing direct and secondary tumour cell 
death. This group hypothesised that hyperoxygenation oxygenated preexisting 
hypoxic cells and compensated for oxygen depletion during PDT [9]. Nevertheless, 
an obvious disadvantage of HBO is the practical feasibility [11] as a custom-built 
chamber is required and the authors also highlighted that if a hypoxic region is too 
far away for oxygen diffusion to take effect then improvement may be limited [9]. 
 
In this study although the greatest level of pre irradiation PpIX fluorescence (Fig. 1), 
and as a result the greatest observed PpIX photobleaching (Fig. 2), was found when 
cells were incubated with MAL + CP94 under hyperoxic conditions (40%) analysis of 
the subsequent cell viability measurements (Fig. 3) following light irradiation did not 
find increased cell death when 40% oxygen was employed. Nevertheless cell 
viability was only assessed at one time point, likely only measuring immediate 
necrotic cell death, therefore to measure levels of apoptotic cell death assessment at 
longer time points following irradiation should be considered in future investigations. 
Alternatively, as it was not possible to measure oxygen concentration within the wells 
following pro-drug treatment it is possible that fluctuations in oxygen concentration 
occurred when the plates (albeit taped shut) were removed from the incubator for 
analysis. Although it is unlikely that this would have had a significant effect on PpIX 
accumulation over the previous 3 h incubation period, it may have adversely effected 
the oxygen concentration during the period of irradiation and thus treatment efficacy. 
  
When ALA and MAL were administered alone no significant differences in cellular 
viability were observed with the three different oxygen concentrations investigated 
(Fig. 3), however when CP94 was administered with ALA or HAL significantly more 
cell death occurred at 20% oxygen + CP94 than at 40% oxygen + CP94 (Fig. 3). 
Although unexpected this latter result may be due to oxygen dependent effects on 
the haem biosynthesis pathway.  
 
These preliminary in vitro findings suggest current dermatological PpIX-induced PDT 
regimens, carried out under normal atmospheric oxygen (∼21%) conditions do not 
have a detrimental effect on efficacy but with further investigation the efficiency of 
PDT might be improved by employing iron chelation and maintaining sufficient 
oxygen availability during PpIX-induced PDT treatment. In this study iron chelation 
significantly increased PpIX photobleaching which corresponded to the increased 
accumulation of PpIX detected pre irradiation with the addition of CP94 to each 
congener and supports the findings of previous work [22-25]. In addition, these in 
vitro results suggest at 20% oxygen the use of HAL, which was used at much lower 
concentrations than either ALA or MAL, should also be considered for topical PDT. It 
has been demonstrated previously that with increasing concentrations of ALA a rise 
to plateau in PpIX fluorescence was observed [22] and previous work from our group 
have shown this to be when the concentration of ALA increases above 250 M [26]. 
In addition, above 10 M HAL dark cytotoxicity has been observed [12] and so much 
smaller concentrations of this ester derivative are therefore employed. This is 
supported by results from an in vivo study on human basal cell carcinomas which 
demonstrated for application times of up to 24 h, HAL was identical to ALA as a PpIX 
precursor with respect to PpIX fluorescence intensity, depth of penetration, and 
distribution within the basal cell carcinoma, but had the added advantage that much 
smaller concentrations of HAL could be used [27]. In this study a significant  
decrease (p < 0.05) in cell viability was observed when HAL ± CP94 was incubated 
at 20% oxygen compared to either 5% or 40% oxygen suggesting greater cell 
ablation may be achieved in vivo.   
 
It is important to remember, however, that in vitro results cannot be extrapolated into, 
for example, a dermatology clinic without supporting in vivo work because within 
multi-well plates effects are taking place within a closed system whilst in vivo there 
are many factors to be taken into consideration. For example, the heterogeneity of 
oxygenation due to micro- environmental differences in inter-capillary distance and 
pre-existing hypoxia which vary depending on the target tissue [28]. In addition, PDT 
can itself induce hypoxia but to date the current understanding of the role of hypoxia 
pre-, during- and post-PDT is limited. One group studied the relationship of tumour 
hypoxia and response to PDT in an experimental mouse model (radiationinduced 
fibrosarcoma tumour (RIF)) [19]. They concluded that considering the reduced 
effectiveness of photodynamic cell ablation at low oxygen concentrations, the rapid 
induction of tumour hypoxia by PDT itself, and the high tumour cure rate (81%) 
observed in their study, that in the RIF tumour, hypoxic tumour cells are inactivated 
by a mechanism other than direct photodynamic cytotoxicity [19]. This could be 
explained by the suggestion that hypoxia can induce necrosis via ATP depletion 
within cells [29]; implying PDT efficacy may be enhanced if hypoxia is induced by 
light irradiation. On the other hand, hypoxia has been shown to stabilise HIF-
1which in turn increases VEGF expression, with the increased production and 
secretion of the latter thought to contribute to tumour survival and regrowth via the 
promotion of angiogenesis, glycolysis, erythropoiesis and apoptotic inhibition [7]. In 
conclusion, the hypothesis that the efficiency of PpIX-induced PDT might be 
improved by sustaining a replete oxygen environment during treatment, not only for 
supporting ROS and singlet oxygen consumption, but also for inhibiting angiogenesis 
requires further investigation. In particular, in vivo studies are required to further 
investigate the clinical use of PDT with oxygen manipulation.   
 
In conclusion, experimentation with human squamous epithelial carcinoma cells has 
indicated that the iron chelator CP94 significantly increased PpIX accumulation 
induced by each PpIX congener investigated (ALA/MAL/HAL) at all oxygen   
concentrations employed (5%/20%/40%) resulting in increased levels of 
photobleaching and reduced cell viability on irradiation. Further detailed investigation 
of the complex relationship of PDT cytotoxicity at various oxygen concentrations is 
required. It is therefore concluded that iron chelation with CP94 is a simple protocol 
modification with which it may be much easier to enhance clinical PDT efficacy than 
the complex and less well understood process of oxygen manipulation. 
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Figure 1 Levels of PpIX fluorescence measured prior to (pre) and following (post) 
light irradiation of human squamous epithelial carcinoma (A431) cells subjected to 
5%, 20% or 40% oxygen and incubated with: (A) 250 M ALA, (B) 250 M ALA + 
CP94 (C) 1000 M MAL (D) 1000 M MAL + CP94, (E) 10 M HAL and (F) 10 M 
HAL + CP94. Data represents the mean of 5 wells ± 1 standard deviation, carried out 
in triplicate (n = 3). *Represents a significant accumulation of PpIX between cells 
incubated with ALA/MAL/HAL alone and cells incubated with ALA/MAL/HAL + CP94 
(p < 0.05).  
 
Figure 2 Bar-charts showing the percentage of preirradiation PpIX levels bleached 
following irradiation (A), and the absolute level of PpIX bleached in arbitrary units 
(B) in human squamous epithelial carcinoma (A431) cells subjected to 5%, 20% or 
40% oxygen and incubated with ALA/MAL/HAL ± CP94. Data represents the mean 
of 5 wells ± 1 standard deviation, carried out in triplicate (n = 3). *Represents 
a significant increase in PpIX photobleaching between cells incubated with 
ALA/MAL/HAL alone and cells incubated with ALA/MAL/HAL + CP94 (p < 0.05). 
 
Figure 3 Cell viability of human squamous epithelial carcinoma (A431) cells 
(presented as a percentage of the blank control) following: (A) ALA ± CP94 PDT-
treatment, (B) MAL ± CP94 PDT-treatment and (C) HAL ± CP94 PDT-treatment. 
Data represents the mean of 5 wells ± 1 standard deviation, carried out in triplicate 
(n = 3). *Represents a significant difference in cell viability (p < 0.05). 
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